19 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Immunotherapy
  • Germany
  • Product Initiative
  • Anergis SA

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Ophthalmology
  • United States
  • World
  • Product Initiative

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Allergy Immunotherapy
  • World
  • Product Initiative
  • Anergis SA

PATIENTS WERE RANDOMIZED IN A ##:## FASHION TO ACTIVE DRUG VERSUS PLACEBO.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • Ophthalmology
  • Therapy

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Ophthalmology
  • Therapy
  • Aimmune Therapeutics, Inc.

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Biotechnology
  • Immunotherapy
  • United States
  • Product Initiative

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Ophthalmology
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Ophthalmology
  • Biomay AG

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Chronic Disease
  • Ophthalmology
  • World
  • Product Initiative

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Allergy
  • Medical Biotechnology
  • Ophthalmology
  • World
  • Product Initiative

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Allergy
  • Medical Biotechnology
  • Ophthalmology
  • World
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Biotechnology
  • Immunotherapy
  • United States
  • Product Initiative

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy
  • Allergy Drug
  • Eye Disease
  • Ophthalmic Solution
  • Ophthalmology

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Allergy
  • Antifungal
  • Ophthalmic Solution
  • Ophthalmology
  • Therapy

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Allergy
  • Antifungal
  • Ophthalmic Solution
  • Ophthalmology
  • Pharmaceutical

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Allergy
  • Antifungal
  • Monoclonal Antibody
  • Ophthalmology
  • SCYNEXIS, Inc.

Subjects orally took study drug once daily in the evening for one month.

  • Allergy
  • Eye Disease
  • Gene Therapy
  • Ophthalmology
  • Therapy

Subjects orally took study drug once daily in the evening for one month.

  • Allergy
  • Eye Disease
  • Ophthalmology
  • United States
  • Product Initiative

(allergy and autoimmune diagnostics) which was sold to Thermo Fisher Scientific (TMO) in September of 2011.

  • Allergy
  • Gene Therapy
  • Ophthalmology
  • Pharmaceutical
  • Therapy